Urgent Supply Notice
Mounjaro price changes explained
Mounjaro prices are increasing across the UK from 1 September 2025
Wegovy is now a much more affordable option — offering significant savings per pen
No need to restart — we’ll match your Wegovy dose to your current Mounjaro so treatment continues smoothly.
Wegovy from £92
Your questions answered
Why are prices increasing?
Eli Lilly has increased prices for all providers, which affects treatment costs. We’re working to keep pricing as competitive as possible ahead of changes from 1 September.
When do the new Mounjaro prices start?
We’re finalising our updated pricing. No changes apply before 31 August, subject to stock. We’ll publish updates once confirmed.
What if I can’t afford Mounjaro?
Some patients can remain on Mounjaro at a lower dose to reduce cost. Others may consider alternatives such as Wegovy or Saxenda. Trials suggest average weight loss of ~17% with Wegovy; individual results vary. Our clinical team can help you choose a suitable option.
Is Wegovy as effective as Mounjaro?
Both are effective. Trials suggest ~20% average weight loss with Mounjaro and ~17% with Wegovy. The best choice depends on tolerability, goals, and budget.
If I switch to Wegovy, will I get similar results?
Yes—Wegovy is a potent treatment. Pen dose numbers aren’t directly comparable across different medicines. What matters is the medicine, the right dose for that medicine, and consistency over time.
Can I switch directly from Mounjaro to Wegovy?
Yes. A 1-week (7-day) wash-out is typically advised before starting Wegovy. Your prescriber will confirm the timing that’s right for you.
Why is a wash-out needed?
To avoid overlapping effects and reduce the risk of side effects.
How long is the wash-out for each Mounjaro dose?
Generally 1 week (7 days) across dose levels.
Do I need a new consultation to switch?
Yes. Mounjaro (tirzepatide) and Wegovy (semaglutide) are different medicines, so a new consultation is required.
Can I switch back to Mounjaro later?
Yes. Follow the same 1-week wash-out and your prescriber’s guidance.
Can I switch mid-cycle?
Yes, but you must start the starter dose of the new medicine.
What if I start Wegovy too soon?
Overlapping effects can increase side-effect risk and make dose titration harder to interpret.
What if I delay starting Wegovy?
It’s safe to delay beyond one week, but appetite may increase and some weight regain can occur. Keeping healthy habits helps mitigate this.
Do I start Wegovy at the same strength as my Mounjaro dose?
No. Begin at 0.25 mg once weekly, regardless of your previous Mounjaro dose.
What is the Wegovy dose-escalation schedule?
0.25 mg weekly × 4 weeks → 0.5 mg × 4 → 1 mg × 4 → 1.7 mg × 4 → 2.4 mg maintenance. Some patients may remain longer at a given dose if effective and well-tolerated (at prescriber discretion).
How will I know if Wegovy is working?
Track hunger, satiety, and weight trends. Some patients see stronger effects at higher doses.
Will I regain weight during the wash-out?
Unlikely over one week, but appetite may rise temporarily until your Wegovy dose becomes effective.
Can I get support during the transition?
Yes—our pharmacists and dietitians are here to help throughout.
Are there symptoms to watch for?
Common GI effects (nausea, diarrhoea/constipation, abdominal discomfort) are similar with both. Stay well hydrated and contact us if symptoms are significant or persistent.
Anything to avoid while switching?
Maintain healthy routines, avoid known trigger foods, and continue regular activity as tolerated.
Can I switch if I had side effects on Mounjaro?
It depends on the side effects. Please speak to a clinician before switching.
Do I need a new prescription?
Yes—your prescriber must confirm suitability for Wegovy and issue a new prescription.
Is Wegovy safe long-term after Mounjaro?
Specific long-term data on switching are limited, but the overall risk profile is expected to be similar to starting Wegovy directly.
What if I miss my first Wegovy dose?
That’s okay. Start the 0.25 mg dose when ready, provided you’ve observed the 1-week wash-out. Longer delays may increase appetite temporarily.
Will switching affect future eligibility?
No. Eligibility is assessed case by case; switching itself doesn’t prevent future treatment.
This information is for existing patients and does not replace medical advice. Always follow your prescriber’s instructions.
Compare weight-management treatments
Key facts at a glance. Choose a treatment to start your consultation.
| Feature | Wegovy (Semaglutide) Avg loss ~15%* |
Mounjaro (Tirzepatide) Avg loss ~20.9%* |
Saxenda (Liraglutide) Avg loss ~10% |
|---|---|---|---|
| Cost | £92–£229/month | £146 / month | £124.99 / month |
| Licensed indication | Weight management | Weight management | Weight management |
| Dosage form | Prefilled injectable pen | Prefilled injectable pen | Prefilled injectable pen |
| Dosing frequency | Once weekly | Once weekly | Once daily |
| Starting dose | 0.25 mg | 2.5 mg | 0.6 mg |
| Maintenance doses | Up to 2.4 mg | Up to 15 mg | Up to 3.0 mg |
| Injection site | Abdomen, thigh, upper arm | Abdomen, thigh, upper arm | Abdomen, thigh, upper arm |
| Avg. weight loss* | Up to 15%* | Up to 20.9%* | ~10% |
| Suitable with oral contraception? | Yes | No | — |
| Injection site reactions† | 0.3% of patients | 8.6% of patients | — |
| Licensed for heart health‡ | Yes | No | — |
| Proven in chronic kidney disease | Yes | No | — |
| Order | Check Eligibility | Check Eligibility | Check Eligibility |
* Effectiveness: In studies, the highest dose of Mounjaro led to an average weight loss of up to 20.9% in 36 weeks and 25.3% in 88 weeks (SURMOUNT-1 & SURMOUNT-2). Wegovy users lost around 15% in 68 weeks (STEP-1).
† Injection site reactions: 0.3% of Wegovy users, 8.6% of Mounjaro users.
‡ Heart health: Wegovy reduced risk of heart attack, stroke and CV death by up to 20% in patients with obesity and existing heart disease (SELECT trial, NEJM 2023).
§ Chronic kidney disease: Wegovy (semaglutide) slowed CKD progression in patients with T2D (FLOW trial, NEJM 2024).
Wegovy (Semaglutide) Avg loss ~15%*
Mounjaro (Tirzepatide) Avg loss ~20.9%*
Saxenda (Liraglutide) Avg loss ~10%
* Effectiveness: Mounjaro – SURMOUNT-1 & SURMOUNT-2 trials (20.9% at 36 weeks; 25.3% at 88 weeks). Wegovy – STEP-1 trial (~15% at 68 weeks).
† Injection site reactions: Wegovy (0.3%), Mounjaro (8.6%).
‡ Heart health: SELECT outcomes trial (NEJM 2023) – Wegovy reduced CV events by ~20%.
§ CKD: FLOW trial (NEJM 2024) – Wegovy slowed CKD progression in T2D patients.
Can I switch to Wegovy?
Yes. Switching between GLP-1 medications is a safe and common medical practice. Our team’s priority is to ensure you receive the most effective treatment tailored to your needs.
Why Wegovy?
Clinically proven results. Studies show patients lose, on average, around 15% of their body weight over 68 weeks with Wegovy.
No need to start over. We’ll transition you to the most appropriate Wegovy dose based on your current Mounjaro treatment — so your progress continues seamlessly.
Additional Benefits of Wegovy
Lower cost: Now significantly less expensive per pen.
Heart health: The first GLP-1 licensed with proven cardiovascular benefits.
Flexibility: Safe for use alongside oral contraception.
Comfort: Often associated with fewer injection-site reactions.
Mounjaro to Wegovy Dose Comparison Tool
Select your current Mounjaro dose:
Click a dose to see the suggested Wegovy equivalent (and step-down option if applicable).
A prescriber will review your dose to ensure it’s safe and appropriate before your order is dispensed.
Your medical team
Backed by our team of highly experienced in-house medical and clinical experts.
Trishla Shah
Trishla is experienced in the NHS, specialising in women's health, sexual health, and weight management. As the Clinical Lead at My London Pharmacy, she expertly manages reproductive health, contraception, STI prevention, and GLP-1 weight loss treatments.
Anthony Rozario
Anthony is an Independent Prescriber specialising at My London Pharmacy, in women's health, skin health and weight management, including GLP-1 weight loss treatments.
Yousef Yaghoubi
Yousef Yaghoubi, the Superintendent Pharmacist and founder of My London Pharmacy has extensive experience in women's health, sexual health, and weight management, ensuring the highest standards of patient care.
Zeenah Araim
Zeenah Araim, an Independent Prescriber, obtained her postgraduate diploma in Independent Prescribing from the University of Hertfordshire in the last three years. She has experience in managing minor ailments and prescribing weight loss treatments.
Amir Habelhames
Amir is a qualified pharmacist with over five years of experience in community care, specialising in minor ailments and skin conditions through PGDs. He has over eight months of experience with GLP-1 therapies for weight management and continues to build expertise in men’s health, hair loss, and skin infections.